Teladoc Health (TDOC) Projected to Post Earnings on Wednesday

Teladoc Health (NYSE:TDOC) will likely be releasing its Q1 2026 results after the market closes on Wednesday, April 29th. Analysts expect Teladoc Health to post earnings of ($0.3412) per share and revenue of $613.8170 million for the quarter. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Wednesday, April 29, 2026 at 5:00 PM ET.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Wednesday, February 25th. The health services provider reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. Teladoc Health had a negative return on equity of 9.13% and a negative net margin of 7.92%.The firm had revenue of $642.27 million during the quarter, compared to analysts’ expectations of $635.33 million. During the same quarter in the prior year, the business posted ($0.28) earnings per share. Teladoc Health’s revenue was up .3% compared to the same quarter last year. On average, analysts expect Teladoc Health to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Teladoc Health Price Performance

Teladoc Health stock opened at $6.00 on Wednesday. The company has a market cap of $1.08 billion, a P/E ratio of -5.26 and a beta of 2.07. Teladoc Health has a one year low of $4.40 and a one year high of $9.77. The business has a fifty day moving average of $5.22 and a two-hundred day moving average of $6.57. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.67 and a current ratio of 2.77.

Wall Street Analyst Weigh In

TDOC has been the subject of a number of research analyst reports. Bank of America upgraded shares of Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 price target for the company in a report on Thursday, February 26th. Piper Sandler reissued an “overweight” rating and set a $9.00 price objective (down from $12.00) on shares of Teladoc Health in a report on Thursday, February 26th. TD Cowen lowered their target price on shares of Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research report on Thursday, February 26th. BMO Capital Markets dropped their target price on shares of Teladoc Health from $8.00 to $5.00 and set a “market perform” rating for the company in a report on Thursday, February 26th. Finally, JPMorgan Chase & Co. reduced their price target on shares of Teladoc Health from $9.00 to $7.00 and set a “neutral” rating for the company in a research report on Friday, March 13th. Six investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $7.62.

Insider Buying and Selling

In other Teladoc Health news, CEO Charles Divita III sold 27,731 shares of the firm’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $5.49, for a total transaction of $152,243.19. Following the completion of the transaction, the chief executive officer directly owned 364,784 shares in the company, valued at approximately $2,002,664.16. This trade represents a 7.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.70% of the company’s stock.

Institutional Trading of Teladoc Health

Several institutional investors and hedge funds have recently modified their holdings of TDOC. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Teladoc Health by 2.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 193,714 shares of the health services provider’s stock worth $1,542,000 after purchasing an additional 5,235 shares in the last quarter. NewEdge Advisors LLC raised its position in shares of Teladoc Health by 1,278.7% during the 1st quarter. NewEdge Advisors LLC now owns 11,305 shares of the health services provider’s stock worth $90,000 after purchasing an additional 10,485 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Teladoc Health by 5.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 447,992 shares of the health services provider’s stock valued at $3,566,000 after buying an additional 24,124 shares in the last quarter. Acadian Asset Management LLC acquired a new stake in Teladoc Health during the 1st quarter valued at $615,000. Finally, Envestnet Asset Management Inc. acquired a new stake in Teladoc Health during the 2nd quarter valued at $89,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.